Key result
Case-based review guides diagnosis and management of cardiac dysfunction from anthracyclines, HER2 therapies, and ICIs.
Why the study?
With expanding cancer therapies, cardiologists increasingly encounter cancer therapy-related cardiac dysfunction, necessitating a multidisciplinary approach and practical clinical guidance.
This review provides a practical guide for the multidisciplinary diagnosis and management of cardiac dysfunction related to common cancer therapies.
May aid cardio-oncology teams managing therapy-related dysfunction; leaves open need for prospective validation of recommendations.
With an ever-expanding repertoire of cancer therapies, cardiologists increasingly encounter patients with cancer therapy-related cardiac dysfunction. This can range from asymptomatic mild left ventricular dysfunction to severe symptomatic congestive heart failure. A multidisciplinary approach involving oncologists and cardiologists is needed in the management of these patients. This case-based review provides a practical guide for clinicians regarding the diagnosis and management of cancer therapy-related cardiac dysfunction associated with commonly used cancer treatments: anthracyclines, human epidermal receptor 2-targeted therapies, and immune checkpoint inhibitors.
No takes yet. Share an insight, caveat, or question.
Baylis et al. (2024) conducted a review in Cancer therapy-related cardiac dysfunction. Management of cancer therapy-related cardiac dysfunction was evaluated. This case-based review provides a practical guide for the diagnosis and management of cancer therapy-related cardiac dysfunction associated with anthracyclines, HER2 therapies, and ICIs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: